Pharmaceuticals company GlaxoSmithKline Pharmaceuticals announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: The company reported a revenue of Rs 966 crore, a like-to-like growth of 6%. Profit After Tax for the quarter stood at Rs 260 crore. FY25 Financial Highlights: The company reported full year revenue of Rs 3,723 crore, a growth of 9%. Profit After Tax before exceptional items increased by 32% to Rs 915 crore EBITDA margins increased by 500 basis points (bps) to 31.4%. Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals, said, “Our diversified portfolio of General Medicines, Specialty, and Vaccines has shown improved growth due to sustained innovation, enhanced Healthcare Professionals (HCP) engagement and rapid digital acceleration. This has enhanced reach, expanded coverage, and provided a seamless omnichannel experience for our customeRs Our key brands, including Augmentin, Calpol, Ceftum, T-Bact, and Trelegy, have played a significant role in driving growth throughout the year. Shingrix is experiencing increased adoption, driven by heightened awareness and our efforts to develop the adult vaccination ecosystem in the country.” “We remain committed to delivering sustained above-market growth and strong shareholder returns. In FY2025-26, we will continue to focus on our innovative portfolio through the launch of our oncology assets,” he added. Result PDF